78. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010; 142:409- 19; PMID:20673990; http://dx.doi.org/10.1016/j. cell.2010.06.040. 79. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, et al. Extensive and coordinated transcrip- tion of noncoding RNAs within cell cycle promoters. Nat Genet 2011; 43:621-9; PMID:21642992; http:// dx.doi.org/10.1038/ng.848. 80. Abrajano JJ, Qureshi IA, Gokhan S, Zheng D, Bergman A, Mehler MF. Differential deployment of REST and CoREST promotes glial subtype specification and oligodendrocyte lineage maturation. PLoS One 2009; 4:7665; PMID:19888342; http://dx.doi.org/10.1371/ journal.pone.0007665. 81. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329:689-93; PMID:20616235; http://dx.doi. org/10.1126/science.1192002. 82. Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle 2006; 5:1929-35; PMID:16929174; http://dx.doi. org/10.4161/cc.5.17.2982. 83. Lawinger P, Venugopal R, Guo ZS, Immaneni A, Sengupta D, Lu W, et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblasto- ma cells. Nat Med 2000; 6:826-31; PMID:10888935; http://dx.doi.org/10.1038/77565. 84. Coulson JM. Transcriptional regulation: cancer, neurons and the REST. Curr Biol 2005; 15:665- 8; PMID:16139198; http://dx.doi.org/10.1016/j. cub.2005.08.032. 85. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008; 4:1000242; PMID:18974828; http://dx.doi.org/10.1371/journal. pgen.1000242. 86. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science 2008; 322:750-6; PMID:18974356; http://dx.doi.org/10.1126/sci- ence.1163045. 87. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2011; 30:1956-62; PMID:21151178; http://dx.doi. org/10.1038/onc.2010.568. 88. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metas- tasis. Nature 2010; 464:1071-6; PMID:20393566; http://dx.doi.org/10.1038/nature08975. 89. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-6; PMID:20601953; http:// dx.doi.org/10.1038/ng.621. 90. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17:2613-8; PMID:21367748; http://dx.doi.org/10.1158/1078-0432.CCR-10-2156. 91. Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, et al. Enhancer of Zeste 2 (EZH2) is upregu- lated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 2011; 37:381-94; PMID:20946108; http://dx.doi.org/10.1111/j.1365- 2990.2010.01132.x. 92. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 2003; 88:5119-26; PMID:14602737; http://dx.doi.org/10.1210/jc.2003- 030222. 93. Kinzler KW, Bigner SH, Bigner DD, Trent JM, Law ML, O’Brien SJ, et al. Identification of an amplified, highly expressed gene in a human glioma. Science 1987; 236:70-3; PMID:3563490; http://dx.doi. org/10.1126/science.3563490. 94. Berteaux N, Aptel N, Cathala G, Genton C, Coll J, Daccache A, et al. A novel H19 antisense RNA overexpressed in breast cancer contributes to pater- nal IGF2 expression. Mol Cell Biol 2008; 28:6731- 45; PMID:18794369; http://dx.doi.org/10.1128/ MCB.02103-07. 95. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75:280-4; PMID:75545; http://dx.doi. org/10.1073/pnas.75.1.280. 96. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A, et al.; Trabedersen Glioma Study Group. Targeted therapy for high-grade glioma with the TGFβ2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13:132-42; PMID:20980335; http:// dx.doi.org/10.1093/neuonc/noq142. 97. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8; PMID:11373684; http://dx.doi.org/10.1038/35078107. 98. Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP, Magistri M, Brothers SP, et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat Biotechnol 2012; In press; PMID:22446693; http://dx.doi.org/10.1038/ nbt.2158. 99. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Inhibition of coagulation by a phosphorothio- ate oligonucleotide. Antisense Nucleic Acid Drug Dev 1997; 7:503-10; PMID:9361909; http://dx.doi. org/10.1089/oli.1.1997.7.503. 100. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bac- terial DNA trigger direct B-cell activation. Nature 1995; 374:546-9; PMID:7700380; http://dx.doi. org/10.1038/374546a0. 101. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate- oligodeoxynucleotides. J Clin Invest 1996; 98:1119- 29; PMID:8787674; http://dx.doi.org/10.1172/ JCI118894. 102. Prasad V, Hashim S, Mukhopadhyay A, Basu SK, Roy RP. Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-spe- cific antisense oligonucleotide. Antimicrob Agents Chemother 1999; 43:2689-96; PMID:10543748. 103. Agrawal S, Zhao Q, Jiang Z, Oliver C, Giles H, Heath J, et al. Toxicologic effects of an oligodeoxynucleotide- phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev 1997; 7:575-84; PMID:9450915; http://dx.doi. org/10.1089/oli.1.1997.7.575. 104. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, et al. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neu- rons from excitotoxicity and reduce focal ischaemic infarctions. Nature 1993; 363:260-3; PMID:8487863; http://dx.doi.org/10.1038/363260a0. 105. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 1993; 259:528-31; PMID:8380941; http://dx.doi. org/10.1126/science.8380941. 106. Chauhan NB, Siegel GJ. Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. Neuroscience 2007; 146:143-51; PMID:17303345; http://dx.doi.org/10.1016/j.neuro- science.2007.01.008. 107. Luo MC, Zhang DQ, Ma SW, Huang YY, Shuster SJ, Porreca F, et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neu- rons. Mol Pain 2005; 1:29; PMID:16191203; http:// dx.doi.org/10.1186/1744-8069-1-29. 108. Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. SciTransl Med 2011; 3:72; PMID:21368223; http://dx.doi.org/10.1126/scitrans- lmed.3001777. 109. Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116:2290-6; PMID:16878173; http://dx.doi. org/10.1172/JCI25424. 110. Standifer KM, Chien CC, Wahlestedt C, Brown GP, Pasternak GW. Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron 1994; 12:805-10; PMID:8161452; http://dx.doi.org/10.1016/0896- 6273(94)90333-6. 111. Thakker DR, Natt F, Hüsken D, Maier R, Müller M, van der Putten H, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interfer- ence. Proc Natl Acad Sci USA 2004; 101:17270- 5; PMID:15569935; http://dx.doi.org/10.1073/ pnas.0406214101. 112. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, O’Dowd BF, et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci USA 2009; 106:21377-82; PMID:19948956; http:// dx.doi.org/10.1073/pnas.0903676106. 113. Choi DC, Maguschak KA, Ye K, Jang SW, Myers KM, Ressler KJ. Prelimbic cortical BDNF is required for memory of learned fear but not extinction or innate fear. Proc Natl Acad Sci USA 2010; 107:2675- 80; PMID:20133801; http://dx.doi.org/10.1073/ pnas.0909359107. 114. Antal A, Chaieb L, Moliadze V, Monte-Silva K, Poreisz C, Thirugnanasambandam N, et al. Brain-derived neurotrophic factor (BDNF) gene polymorphisms shape cortical plasticity in humans. Brain Stimul 2010; 3:230-7; PMID:20965453; http://dx.doi. org/10.1016/j.brs.2009.12.003. 115. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, et al. Small molecule BDNF mimetics activate TrkB sig- naling and prevent neuronal degeneration in rodents. J Clin Invest 2010; 120:1774-85; PMID:20407211; http://dx.doi.org/10.1172/JCI41356. 116. Laske C, StellosK, Hoffmann N, Stransky E, Straten G, Eschweiler GW, et al. Higher BDNF serum levels predict slower cognitive decline in Alzheimer’s disease patients. Int J Neuropsychopharmacol 2011; 14:399- 404; PMID:20860877; http://dx.doi.org/10.1017/ S1461145710001008. 117. Dell’Osso L, Del Debbio A, Veltri A, Bianchi C, Roncaglia I, Carlini M, et al. Associations between brain-derived neurotrophic factor plasma levels and severity of the illness, recurrence and symp- toms in depressed patients. Neuropsychobiology 2010; 62:207-12; PMID:20714169; http://dx.doi. org/10.1159/000319946. 118. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 1991; 7:695-702; PMID:1742020; http://dx.doi.org/10.1016/0896-6273(91)90273-3. 119. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 2009; 15:331-7; PMID:19198615; http://dx.doi. org/10.1038/nm.1912. www.landesbioscience.com rNA Biology 869